Morgan Stanley Downgrades Mural Oncology (NASDAQ:MURA) to Equal Weight

Mural Oncology (NASDAQ:MURA) was downgraded by stock analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Tuesday, Marketbeat.com reports.

A number of other analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a research note on Wednesday, March 12th. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research report on Tuesday. Finally, Raymond James cut shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Mural Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Mural Oncology Stock Down 9.5 %

Mural Oncology stock opened at $1.33 on Tuesday. Mural Oncology has a 52-week low of $1.30 and a 52-week high of $5.12. The firm has a market cap of $22.91 million, a PE ratio of -0.15 and a beta of 3.66. The company’s 50 day moving average is $3.82 and its two-hundred day moving average is $3.60.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the business posted ($3.57) earnings per share. On average, equities research analysts anticipate that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Trading of Mural Oncology

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC lifted its holdings in shares of Mural Oncology by 1.4% in the 4th quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock valued at $565,000 after purchasing an additional 2,470 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Mural Oncology in the fourth quarter valued at approximately $84,000. Two Sigma Investments LP grew its position in shares of Mural Oncology by 12.0% during the fourth quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock worth $210,000 after acquiring an additional 6,993 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in shares of Mural Oncology in the 4th quarter valued at $94,000. Finally, Acorn Capital Advisors LLC purchased a new stake in Mural Oncology in the 4th quarter valued at $4,141,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.